Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Summary

The POLE mutations represent high somatic mutation loads in patients with colorectal cancer, especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations might be susceptible to immune checkpoint blockade. Based on these reasons, Investigator planned a phase II study of avelumab monotherapy in patients with previously treated, metastatic, MMR deficient (MSI-H) or POLE mutated colorectal cancer.

Timeline

Start

2017-05-22

Primary completion

2021-07-31

Completion

2021-12-31

Drugs

Indications